Xenon Pharmaceuticals shareholders approve 2026 equity plan and elect eight directors
At its annual meeting on June 2, 2026, Xenon Pharmaceuticals shareholders approved a new 2026 Equity Incentive Plan to replace the 2014 plan, and elected all eight director nominees. Shareholders also approved the auditor appointment and backed an annual frequency for future say-on-pay votes on executive pay.
Key points
- Shareholders holding about 93.54% of the company's total voting common shares were present or represented at the meeting.
- The 2026 Equity Incentive Plan received 58,579,810 votes for and 27,570,443.18 votes against, with 842,250 abstentions.
- Eight directors, including Dawn Svoronos and Patrick Machado, were elected to serve until the 2027 annual meeting.
- Shareholders voted for a one-year frequency for say-on-pay votes, with 86,918,084.18 votes, and PricewaterhouseCoopers LLP was approved as auditor.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.